Abstracts

HIV and Tuberculosis in Kenya *2012-2013: Results from a National Survey

Background: Co-infection with tuberculosis and HIV remains a major cause of morbidity and mortality in sub-Saharan Africa. The 2nd Kenya AIDS Indicator Survey (KAIS 2012) assessed knowledge and experience concerning tuberculosis and HIV at a population level in Kenya, including coverage with treatment services and antiretroviral therapy (ART). Methodology: KAIS 2012 was a national, population-based,…

Identifying Location of Recent TB Transmission in Rural Uganda: A Multidisciplinary Approach

Background: Given the substantial burden of undiagnosed TB in sub-Saharan Africa, novel active TB case finding strategies are needed. Location-based TB case finding offers a potentially high yield, community-based approach. However, the precise locations of recent TB transmission events occurring in rural African communities are largely unknown. Methodology: We recruited all adult residents diagnosed with…

Timing of TB Episodes After the End of Isoniazid Preventive Therapy: Reinfection or Reactivation?

Background: Isoniazid preventive therapy (IPT) reduces tuberculosis (TB) incidence in high risk populations (HIV-positive and negative), but durability of protection is limited in high burden settings. The underlying mechanism (reactivation of persistent latent TB or re-infection) is not well understood. There are few data on long-term TB incidence after IPT discontinuation. This study aimed to…

ss469415590 Variant Is a Better Predictor Than IL28B rs12979860 of PegIFN-α/RBV Therapy Failure

Background: Recently, it has been discovered, upstream of the interferon-λ3 protein (IFNL3) (also termed IL28B) on chromosome 19, a new transiently induced region that harbors a dinucleotide variant ss469415590 (TT or ΔG), which is in high linkage disequilibrium with rs12979860. ss469415590 (ΔG) is a frameshift variant that creates a novel gene, designated IFNL4, which is…

Boceprevir for Previously Treated HCV-HIV Coinfected Patients: the ANRS-HC27 BocepreVIH Trial

Background: Boceprevir (BOC) added to pegylated-interferon (P) and ribavirin (R) increases sustained virological response (SVR) rates in naive hepatitis C virus (HCV) genotype 1/HIV-co-infected patients. There is no data in HCV/HIV-co-infected patients who previously failed PR treatment. Methodology: In this multicenter single arm open-label phase 2 trial, patients received a 4-week lead-in of PR (peg-IFNα2b:1.5…

Pill Burden & Treatment Length Reduce Adherence to IFN-Free Hepatitis C Therapy in an Urban Cohort

Background: Potent oral directly acting antiviral (DAA) HCV therapy with low pill burdens and short therapeutic courses are promising replacements for interferon and ribavirin based regimens. The impact of these improvements on patient adherence and virologic outcomes has not been described. Methodology: Sixty HCV infected, treatment naive, genotype 1 patients were enrolled into 3 arms…

Telaprevir Treatment of HIV/HCV G1 Patients with Severe Fibrosis: Efficacy Results to Week 16

Background: HEP3005 is an ongoing, open-label, international clinical trial of telaprevir for patients with genotype 1 hepatitis C, HIV co-infection, and either severe fibrosis or compensated cirrhosis. Methodology: One-hundred and eighteen patients were treated with telaprevir, pegylated interferon-alpha and ribavirin (PR) for 12 weeks, followed by PR for 36 weeks. Liver biopsy or non-invasive tests…

Telaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients

Background: A significant hematological toxicity (HT) was observed during the retreatment of HIV-HCV genotype 1 coinfected patients in the ANRS HC26 TelapreVIH study. Alterations in renal function have been described with telaprevir (TVR). We examined the relationship between ribavirin (RBV) trough concentration (C), estimated glomerular filtration rate (eGFR) and hemoglobin (Hb) level, before and after…

Pharmacokinetics of Raltegravir 400 vs 800 mg BID with Intermittent Rifampicin Dosed Thrice Weekly

Background: ‘DOTS’ strategies involve directly observed medication intake to maximise adherence to antituberculous therapy (ATT), utilising either daily, or thrice-weekly rifampicin (RIF)-based regimens. In HIV-TB coinfection, raltegravir (RAL) represents an alternative antiretroviral for patients with efavirenz resistance or intolerance. As drug interactions with intermittent RIF regimens have not been studied we evaluated the effect of…